Webinar Cafe
Technology / Lifescience
Kazia Therapeutics Virtual Event: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader
Join Kazia Therapeutics for a virtual event featuring management’s overview of NDL2, the Company’s novel nuclear PD-L1 protein degrader designed to address mechanisms of immu